|

Lung Cancer Clinical Trials in Sacramento, CA

59 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H MutationPhase 1<1 mi
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationPhase 1/2<1 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—<1 mi
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 2<1 mi
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsPhase 1<1 mi
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialPhase 3<1 mi
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)Phase 3<1 mi
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsPhase 1/2<1 mi
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerPhase 1/2<1 mi
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3<1 mi
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation—<1 mi
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)Phase 3<1 mi
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)N/A<1 mi
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCPhase 3<1 mi
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2<1 mi
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2/3<1 mi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Phase 2<1 mi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Phase 2<1 mi
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsPhase 3<1 mi
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Phase 2<1 mi
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyPhase 2<1 mi
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersPhase 2<1 mi
A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPhase 1<1 mi
SW-682 in Advanced Solid TumorsPhase 1<1 mi
Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer—<1 mi
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%Phase 3<1 mi
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerPhase 3<1 mi
The SEQUENCE TrialN/A<1 mi
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3<1 mi
A Study of DB-1310 in Advanced/Metastatic Solid TumorsPhase 1/2<1 mi
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsPhase 1<1 mi
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsPhase 1/2<1 mi
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6Phase 1<1 mi
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3<1 mi
BBO-11818 in Adult Subjects With KRAS Mutant CancerPhase 1<1 mi
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced MalignanciesPhase 1<1 mi
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPhase 3<1 mi
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsPhase 3<1 mi
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung CancerPhase 1<1 mi
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung CancerPhase 1/2<1 mi
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialPhase 3<1 mi
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung CancerPhase 2<1 mi
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 MutationsPhase 1/2<1 mi
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCPhase 1/2<1 mi
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung CancerPhase 1<1 mi
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3<1 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—<1 mi
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaPhase 1<1 mi
Distance-Based Exercise to Preserve Function and Prevent DisabilityN/A<1 mi
ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health—<1 mi
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)Phase 3<1 mi
Patient-Derived Xenografts to Reduce Cancer Health Disparities—<1 mi
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung CancerPhase 313 mi
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their CaregiversN/A14 mi
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsPhase 316 mi
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 316 mi
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 333 mi
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Phase 2/345 mi
BostonGene and Exigent Genomic INsight Study—45 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.